Who is sponsoring NCT00696904?

NCT00696904 is sponsored by AbbVie.

What condition does NCT00696904 study?

NCT00696904 studies HCV Infection.

What drugs are being tested in NCT00696904?

Interventions: ABT-333, Placebo.

What is the status of NCT00696904?

NCT00696904 is currently COMPLETED.

Last reviewed 2017-11-17 · How we verify

Study of ABT-333 in Both Healthy Volunteers and Hepatitis C Virus (HCV) + Genotype 1 Infected Subjects

NCT00696904 Phase 1 COMPLETED

The purpose of this study is to assess the safety, tolerability, pharmacokinetics of ABT-333 in healthy volunteers and the antiviral activity in HCV infected subjects.

Details

Lead sponsor	AbbVie
Phase	Phase 1
Status	COMPLETED
Enrolment	133
Start date	2008-06

Conditions

HCV Infection

Interventions

ABT-333
Placebo

Primary outcomes

Analysis of pharmacokinetic variables and mean change in HCV RNA level from baseline. — approximately 1 week or less
Analysis of safety measures, including but not limited to tabulation of adverse events, physical exam, clinical lab results (include chemistry, hematology and urine) and vital signs. — approximately 1 week